Background The purpose of this study was to evaluate the effects of cytoreductive
nephrectomy (CN) and metastasectomies on the survival of patients with synchronous …

Background/Aim: We performed a retrospective survey on our metastatic renal cell
carcinoma (MRCC) patients who had received targeted therapies, and afterwards evaluated …

Introduction: As new therapeutics for metastatic renal cell carcinoma (mRCC) are quickly
introduced to market, comparative randomized trial evidence guiding treatment decisions is …

Background With the advent of small-molecule “targeted” therapies, the prevailing treatment
paradigm for metastatic renal cell carcinoma (mRCC) is that all patients who are able to …

Over the last decades, the therapeutic armamentarium of metastatic renal cell carcinoma
(mRCC) has been revolutionized by the advent of tyrosin-kinase inhibitors (TKI), immune …

Conclusion Whatever the modest progress made for a small number of patients with MRCC,
the majority of patients will die within 5 years of diagnosis of MRCC. Therefore, there is a …

Background Treatment paradigms for management of metastatic renal cell carcinoma
(mRCC) are evolving. We examined impact of surgical metastasectomy on survival across in …

Background It is unknown if discontinuation of targeted therapy (TT) and readministration in
case of recurrence is feasible in patients with metastatic renal cell carcinoma (mRCC) in …

Background The use of third-line targeted therapy (TTT) in metastatic renal cell carcinoma
(mRCC) is not well characterized and varies due to the lack of robust data to guide treatment …

BACKGROUND The current study was conducted to investigate the dependence between
progression‐free survival (PFS) and overall survival (OS) in patients with metastatic renal …